drugset / Trial / NCT00318552

Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.

NCT00318552

Phase 4 Completed 160 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.

Timeline

Start
2002-01
Primary completion
2006-06
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Meropenem Small molecule